QIAGEN Unveils Diagnostic Assay in the EU to Detect Genetic Variation Causing Adverse Reactions in AIDS Patients
QIAGEN (Nasdaq: QGEN; Frankfurt Prime Standard: QIA) today announced that it has introduced a new molecular diagnostic t…
QIAGEN (Nasdaq: QGEN; Frankfurt Prime Standard: QIA) today announced that it has introduced a new molecular diagnostic t…
"This award confirms our claims that we are a reliable partner to our customers, particularly when it comes to planning…
Allergische Erkrankungen treten häufiger auf bei Kindern, die in der Nähe stark befahrener Straßen aufwachsen. Dies ist…
/pressemitteilung/pdf/24504/meldung.pdf
Das europäische Tuschl-II-Patent deckt siRNA- (short interfering RNA) –beinhaltende Stoffe und Stoffgemische, sowie dies…